DUBLIN--(BUSINESS WIRE)--The "Schistosomiasis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
- Ebelle Pharmaceuticals Inc.
- IRBM Science Park S.p.A.
- Knight Therapeutics Inc.
- Merck KGaA
- Pai Life Sciences Inc.
- Tongli Biomedical Co. Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bpdenz
